Luye Pharma Group (HKG:2186) said its LY01620 therapeutic mRNA vaccine for cervical precancerous lesions is set to enter a Phase II clinical trial in China.
The trial will assess the candidate's safety and efficacy in patients with HPV16-positive high-grade cervical lesions, according to a Thursday Hong Kong exchange filing. Positive results from a Phase I study supported the move into Phase II, the company said in the filing.
Shares of the company rose nearly 2% in recent trade.
ExaWizards' (TYO:4259) wholly owned subsidiary, ExaMD, started a SAKIGAKE comprehensive evaluation consultation with Japan's Pharmaceuticals and Medical Devices Agency (PMDA) for its AI-powered cognitive function diagnostic support app, according to a Friday filing with the Tokyo bourse.The product is a software-as-a-medical-device that analyzes cognitive function from voice data collected via smartphones and other devices, it said.Shares of ExaWizards rose nearly 1% in recent trade.
Omesti (KLSE:OMESTI) proposed to consolidate every five existing shares into one share, according to a Thursday Malaysian bourse filing.As at Aug. 17, Omesti had 2.32 billion shares in issue. Under the minimum scenario, the consolidation will reduce this to 464.5 million shares. If all 131.8 million outstanding warrants are exercised before the consolidation, the enlarged 2.45 billion shares would be consolidated into 490.8 million shares.The entitlement date will be announced later, it said.
Hyundai Motor's (KRX: 005380) full-day labor strike on Friday is estimated to cause 2.3 trillion won in lost sales by halting production at its Ulsan, Jeonju, and Asan plants for 16 hours, Yonhap News reported the same day.About 39,000 union members are walking out after failing to reach a wage agreement with management. The union has staged 60 hours of strikes since May and plans additional four-hour stoppages on Monday and Tuesday, the report said.The ongoing strikes are expected to result in an estimated cumulative production loss of 55,200 vehicles, the report said.Hyundai Motor did not immediately respond to' request for comment.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)